The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
Diet Coke is having a moment as the drink of choice for Donald Trump, but daily consumption may carry risks, including ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...